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BACKGROUND. The objective of this study was to estimate the time to treatment
failure and survival rate of the three-drug combination of doxorubicin, cisplatin,
and ifosfamide as primary and postoperative, adjunctive treatment for teenagers
and adults with osteosarcoma (OS).
METHODS. Sixty-three eligible patients with nonmetastatic OS of the extremities
were registered from 24 institutions from February, 1992 through December, 1996.
Chemotherapy was comprised of doxorubicin at a dose of 75 mg/m2 and cisplatin
at a dose of 120 mg/m2, alternating with doxorubicin at a dose of 50 mg/m2 and
ifosfamide at a dose of 8 g/m2. Four cycles were given prior to surgical resection,
and four cycles were given after surgery. Outcome measures included the time to
treatment failure, overall survival, toxicity, and centralized assessment of tumor
necrosis.
RESULTS. Thirty-one of 63 eligible patients died, for a 5-year overall survival rate of
58% (95% confidence interval [95% CI], 46 –71%). The median time to treatment
failure was 19 months (95% CI, 12– 41 months). A good pathologic response ( 90%
necrosis) to neoadjuvant chemotherapy was observed in 48% of patients who
underwent surgery. There was no correlation noted between response to neoad-
juvant chemotherapy and patient outcome. Grade 4 hematologic toxicities were
frequent (89%), although serious nonhematologic toxicities other than nausea and
emesis were uncommon.
CONCLUSIONS. The regimen and schedule used in the current study did not
improve outcomes compared with prior trials of doxorubicin and cisplatin alone.
New, more effective drugs are needed for the treatment of patients with OS. The
identification and utilization of molecular markers to predict outcome and re-
sponse to therapy would facilitate clinical management, limiting exposure to toxic
therapies for patients with favorable molecular profiles and identifying those
patients who may fail with current approaches as candidates for clinical trials.
Cancer 2004;100:818 –25. © 2004 American Cancer Society.
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H istorically, patients with osteosarcoma (OS) had a dismal progno-sis, with retrospective 5-year survival rates of 15–20%.1,2 In 1970,
Marcove et al. reported on 145 consecutive patients, which has be-
come the standard number for a historic control group.2 The 5-year
disease-free survival rate in that series was 17.4%, with a time from
clinical recognition of metastases to death of approximately 6
months. Since 1978, a number of studies using adjuvant chemother-
apy have documented impressive evidence of an increased disease-
free survival rate in patients with primary OS of the extremity, with
many reports describing the disease as cured in  66 –75% of patients
afflicted.3–12 Agents that are used widely and are accepted as effica-
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cious in patients with OS include doxorubicin, cispla-
tin, and high-dose methotrexate. Neoadjuvant chemo-
therapy followed by surgery with additional adjuvant
chemotherapy has become a common treatment ap-
proach.
Postchemotherapy tumor necrosis has been con-
sidered a significant prognostic indicator by many
authors.10 –15 The histologic assessment of response to
preoperative chemotherapy requires considerable
time, effort, and expertise.16 Most attempts to deter-
mine response to preoperative chemotherapy by esti-
mating tumor necrosis have been done in single-in-
stitution settings.13–15 The feasibility and utility of
evaluating histopathologic necrosis on a group-wide
level at the time of study initiation, however, was
uncertain.
Ifosfamide was evaluated in sarcomas in the late
1980s, with reported activity in patients with advanced
OS.17,18 Based on single-agent activity in patients with
soft tissue sarcoma and enhanced response rates in
combination with doxorubicin, testing ifosfamide as
part of an adjuvant program in OS was deemed ap-
propriate.19,20 In 1991, the Southwest Oncology Group
(SWOG) initiated a Phase II trial combining ifosfamide
with doxorubicin and cisplatin. Based on the per-
ceived primacy of doxorubicin and considering the
overlapping renal toxicity of cisplatin and ifosfamide,
the trial was designed to deliver doxorubicin for eight
cycles in combination with alternating cisplatin and
ifosfamide.21 The objectives of the current trial were to
estimate the survival, time to treatment failure, and
toxicity of this approach in teenage and adult popu-
lations. Secondary objectives included assessing
pathologic necrosis centrally and examining the prog-
nostic utility of percent necrosis after this neoadjuvant
chemotherapy regimen.
MATERIALS AND METHODS
Patients were required to have a histologic diagnosis
of OS of the appendicular skeleton, with registration to
the protocol occurring within 28 days of biopsy. Al-
lowable stages included high-grade, intracompart-
mental or extracompartmental disease without clini-
cal evidence of metastasis. Prestudy computed
tomography scans of the chest and bone scans were
required. Patients had to be age  11 years, with no
upper age limit specified. Adequate bone marrow re-
serve (leukocyte count  3000/L and platelet count
 institutional lower limits), normal renal and hepatic
function (serum creatinine and bilirubin levels  in-
stitutional upper limits of normal), and left ventricular
function ( institutional lower limits of normal on a
prestudy multiple-gated acquisition scan or an echo-
cardiogram) were necessary. A SWOG performance
status of 0 –2 was required. Patients were ineligible if
they had multicentric primary disease, parosteal OS,
periosteal OS, Paget disease, radiation-induced OS, or
recurrent disease. No prior chemotherapy or radiation
therapy for OS was permitted. Pregnant or nursing
women were ineligible, and all participants of repro-
ductive potential agreed to use effective contracep-
tion. All patients were aware of the investigational
nature of the study and provided Institutional Review
Board-approved written informed consent.
Treatment Plan
Needle biopsy or open biopsy to obtain a diagnosis
was accepted. Attention to placement of the biopsy
tract, meticulous hemostasis, the use of methyl
methacrylate if the bone was entered, and resection of
the biopsy tract at the time of definitive surgery were
required.
Chemotherapy was comprised of eight cycles, in-
cluding four preoperative cycles (neoadjuvant chemo-
therapy) and four cycles after surgery (adjuvant che-
motherapy). Courses were to be given at 21-day
intervals or on recovery from toxicity from the previ-
ous cycle. Chemotherapy was comprised of alternat-
ing cycles of doxorubicin/cisplatin and doxorubicin/
ifosfamide. For Cycles 1, 3, 5, and 7, the intended
doxorubicin dose was 75 mg/m2 delivered by a 96-
hour central venous infusion. Cisplatin was given on
Day 1 at a dose of 120 mg/m2 in 3% saline intrave-
nously (i.v.) over 2 hours in odd-numbered cycles.
Patients were hydrated prior to cisplatin and received
mannitol before and after cisplatin infusion. For Cy-
cles 2, 4, 6, and 8, the intended doxorubicin dose was
50 mg/m2 delivered by 96-hour i.v. infusion. Ifosf-
amide was given on Days 1– 4 of each even-numbered
cycle at a dose of 2 g/m2 over 1 hour. Sodium mer-
captoethanesulfonate was given at a dose of 400
mg/m2 by slow i.v. push at 0 hours, 4 hours, and 8
hours around each daily dose of ifosfamide. The pro-
posed treatment plan resulted in a total doxorubicin
dose of 500 mg/m2, a total cisplatin dose of 480 mg/
m2, and a total ifosfamide dose of 32 g/m2. Dose
adjustments for severe toxicity were allowed and were
made cycle-specific for the subsequent odd or even
cycle. For patients who experienced a platelet count
 40,000/L, a leukocyte count  500/L, or admis-
sion to the hospital with neutropenia (neutrophils
 500/L) and fever, doses were reduced one level.
When doses were reduced for toxicity, they were not
increased subsequently. Myeloid growth factors be-
came available during the course of the study, and
their use was allowed at the discretion of the treating
physician.
Definitive surgery was planned after recovery
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from the Cycle 4 of chemotherapy, approximately on
Day 90 of protocol treatment. Margins for resection
and location of transmedullary resection were at the
discretion of the operating surgeon. Amputation or
limb-salvage surgery was acceptable. For patients who
underwent limb salvage, margins were required to be
disease free in the pathology assessment; if not, then
amputation was recommended. Barring complica-
tions, postoperative chemotherapy was to be resumed
within 14 days of the operation.
Pathology Assessment
The protocol required submission of the surgical spec-
imen to a central laboratory for scoring the percent
necrosis after preoperative chemotherapy. After the
removal of excessive soft tissue at the site of surgery,
the specimen was cut longitudinally into 5-mm slabs
by a band saw and was placed in 15% formalin. The
specimen was shipped overnight to Wayne State Uni-
versity for processing. Slab sections were photocopied,
and a grid was drawn on the photocopy to map the
locations of the histologic sections. The entire slab was
decalcified and processed for histology. Whenever
possible, the viable areas and necrotic areas were cir-
cled with a fine-tip felt marker, and the areas of each
were measured semiquantitatively by placing the
slides over graph paper; then, the percent necrosis was
calculated. If a surgical specimen was not sent to the
central laboratory, then the reported institutional per-
cent necrosis values were included in the results
Preoperative Doxorubicin Dose Intensity
Preoperative doxorubicin dose intensity (preop dox
DI) was recorded for all patients who completed four
cycles of neoadjuvant chemotherapy and underwent
protocol-directed surgery. The protocol specified 4 cy-
cles of neoadjuvant doxorubicin (250 mg/m2 total)
delivered in 21-day cycles (84 days). To permit restag-
ing and surgical planning, an additional 7 days were
anticipated and were added to the preoperative inter-
val. Preop dox DI for each patient was calculated using
the formula preop dox DI  (doxorubicin received/
m2/250 mg/m2)  (91 days/number of days from first
treatment to surgery) and was expressed as a percent
intended by the protocol.
Statistical Considerations
Toxicity was evaluated according to standard criteria
of the SWOG.22 The study design called for 60 eligible
patients, with an anticipated annual accrual rate of 20
patients. Survival was measured from the day of reg-
istration on study until death from any cause. The
time to treatment failure was measured from the day
of registration on study until disease progression, re-
moval from treatment due to toxicity, refusal, or death
from any cause. The distributions of survival and time
to treatment failure were estimated by the Kaplan–
Meier method.23 Histologic tumor necrosis to chemo-
therapy, which was scored centrally, was to be used to
evaluate response to preoperative treatment. The re-
sults presented in this report were based on data that
were available September 30, 2002.
RESULTS
Between February 1992 and December 1996, 65 pa-
tients were registered on the study from 24 different
institutions. Two patients were ineligible; one patient
had an axial primary with lung metastasis, and a sec-
ond patient had pulmonary metastasis at the time of
registration. The median follow-up was 79 months for
32 eligible patients who were last reported alive. Of 63
eligible patients, there were 44 males and 19 females.
Ages ranged from 12 years to 70 years, the median age
was 22 years, and 15 patients were age  30 years.
On-study performance status was recorded as 0 in 17
patients (27%), 1 in 40 patients (63%), and 2 in 6
patients (10%). The primary tumor site was the femur
in 32 patients, the tibia in 16 patients, the humerus in
6 patients, and other sites in 9 patients. Tumor histol-
ogy was characterized as OS not otherwise specified in
21 patients, osteoblastic in 19 patients, chondroblastic
in 13 patients, fibroblastic in 7 patients, small cell in 2
patients, and telangiectatic in 1 patient. All but six
patients had extracompartmental (Enneking Stage IIB)
disease. The duration of symptoms prior to diagnosis
was recorded as  1 month in 7 patients (11%), 1– 6
months in 42 patients (67%), and  6 months in 14
patients (22%). Patient and tumor characteristics are
summarized in Table 1.
Fifty-seven eligible patients completed 4 cycles of
preoperative chemotherapy. One patient was given an
incorrect dose of doxorubicin and was taken off treat-
ment because of toxicity. A second patient experi-
enced chest pain after her first cisplatin infusion and
refused further therapy. Four additional patients were
removed from study during primary chemotherapy for
reasons that were not specified in the protocol; two
patients were removed for lack of radiologic responses
in the primary tumor, one patient was removed be-
cause limb salvage was not possible, and one patient
moved to a location where an SWOG institution was
not available for study continuation.
Fifty-six eligible patients underwent protocol-di-
rected surgery. One patient completed preoperative
chemotherapy but refused a recommended amputa-
tion and further treatment. Surgery was performed at
a median of 103 days (range, 83–148 days) after treat-
ment initiation. Surgical specimens for scoring his-
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topathologic necrosis were received by the central lab-
oratory for 44 patients (80%). The median time to
resumption of adjuvant chemotherapy after surgery
was 16 days (range, 10 – 41 days).
Postoperative adjuvant chemotherapy was com-
pleted by 41 patients. Fifteen patients received less
than the planned four courses of adjuvant chemother-
apy for the following reasons: toxicity prompted pa-
tient and physician decision to stop therapy in 5 pa-
tients, refusal to continue by 3 patients, physician
decision to change or stop therapy in 4 patients, dis-
ease progression in 2 patients, and early death in 1
patient.
Survival
Of 63 eligible patients, 31 patients had died by the
time of last follow-up, for a 5-year overall survival rate
of 58% (95% confidence interval [95% CI], 46 –71%)
(Fig. 1). The median overall survival was 86 months
(95% CI, 49 –92 months). All reported deaths were
associated with recurrent OS, including one death on
treatment secondary to toxicity. The median time to
treatment failure was 19 months (95% CI, 12– 41
months) (Fig. 2).
Of 63 eligible patients, 32 patients developed re-
current disease. The most frequent site of recurrence
was lung (80%), although failure occurred locally (5%),
in bone (10%), and in soft tissue (3%). Three patients
had distant disease progression during protocol ther-
apy. Each patient who developed recurrent OS either
had died or was still alive with disease at the time of
last follow-up.
Isolated local failure occurred in 3 of 56 patients
who underwent protocol-directed surgery. One local
failure was in a radius lesion after a poor response to
neoadjuvant chemotherapy (10% necrosis) and a
2-mm soft tissue margin. A second local failure oc-
curred in a femur lesion nearly 6 years after the patient
underwent resection (57% necrosis). The third local
failure occurred despite 100% tumor necrosis in a
patient with a fibular OS, small cell variant.
Toxicity
Of the 63 eligible patients who were evaluable for
toxicities during neoadjuvant chemotherapy, 52 pa-
tients (83%) experienced Grade 4 hematologic toxici-
ties. Seven of those patients (11%) also experienced
Grade 4 nonhematologic toxicities, principally gastro-
intestinal (emesis). Toxicities were similar during
postoperative adjuvant chemotherapy. Of 55 evalu-
able patients, 43 patients (78%) experienced Grade 4
hematologic toxicity and 5 patients (9%) also experi-
enced Grade 4 nonhematologic toxicity. One patient
died from infection with associated, severe myelosup-
pression. Autopsy revealed necrotizing colitis as a
likely cause of death; in addition, severe bone marrow
hypocellularity and two pulmonary metastatic nod-
ules were found. The worst episodes of toxicity expe-
rienced for all eligible patients on study are summa-
rized in Table 2.
TABLE 1
Patient Characteristics




















FIGURE 1. Overall survival in eligible patients with follow-up.
FIGURE 2. The time to treatment failure in eligible patients with follow-up.
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Hematologic toxicities throughout the study were
formidable. Principally, as a consequence of neutro-
penic fever, i.v. antibiotics were required (usually only
once) by 47 patients (75%). Myeloid growth factor was
used in 45 patients (71%) for a median of 5 cycles.
Growth factor use was more common in patients who
had received i.v. antibiotics (87% vs. 44%), reflecting
common practice at that time. Blood transfusions
were required in 34 patients, 15 during neoadjuvant
treatment, 8 in the perioperative period, and 17 during
postoperative adjuvant chemotherapy. Platelet trans-
fusions were required in 12 patients, 6 during neoad-
juvant chemotherapy and 6 during adjuvant treat-
ment. Toxicities contributed to a decision to stop
therapy prematurely in at least 11 patients, as de-
scribed earlier.
Two patients had cisplatin discontinued after Cy-
cles 1 and 3, secondary to tinnitus. There were two
patients in whom Grade 3 increases in creatinine lev-
els were reported, both in the setting of additional
toxicities. Two elderly patients had asymptomatic de-
creases in the ejection fraction below institutional
normal values, prompting cessation of doxorubicin for
Cycles 7 and 8 of therapy; with repeat testing, values
for both patients returned to normal. Other cardiac
toxicities of  Grade 1 were not observed on study or
in follow-up. One middle-aged woman was diagnosed
subsequently with early uterine carcinoma and was
treated effectively. No secondary myelodysplastic syn-
dromes or leukemias were reported.
Surgery and Pathology Assessment
Forty-four patients underwent limb-salvage surgery,
and 12 patients underwent amputation. Amputation
was more common when the primary tumor was in
the tibia (31%) compared with the femur (17%) or
other sites (13%), most likely because of the recon-
structive difficulties in the tibia. Pathologic fracture (2
of 4 patients who underwent amputation) and larger
primary tumor size (median, 10 cm for amputation vs.
8 cm for limb salvage) appeared to influence the like-
lihood of amputation. Response to neoadjuvant che-
motherapy did not appear to influence the surgical
procedure performed. Twenty one of 44 patients who
underwent limb-salvage surgery had  90% necrosis.
In the group who underwent amputation, 6 of 11
patients had  90% necrosis.
Of 56 patients who underwent protocol-directed
surgery, specimens were reviewed by the study pa-
thologist in 44 patients. Amongst those 44 specimens,
there was concordance between institution and study
pathologists in 41 specimens (93%) in assigning a Hu-
vos score ( 90% or  90% necrosis). In 2 specimens,
the originating institution described 100% necrosis
and 92% necrosis; those specimens were character-
ized subsequently by the study pathologist with 67%
necrosis and 70% necrosis, respectively. The final
specimen was graded with 91% necrosis by the insti-
tution and 100% necrosis by the study pathologist.
When materials were not forwarded to the reference
center (12 specimens), the institutional percent necro-
sis was used in this analysis.
There were 17 patients (30%) with  60% necrosis,
29 patients (52%) with  90% necrosis, and 27 patients
(48%) in whom necrosis was estimated at  90%.
Seven patients were assessed with 100% necrosis, with
5 patients surviving free of disease. When analyzed by
the dichotomy of  90% or  90%, there was no
significant difference in survival (P  0.95). There was
a correlation between preop dox DI and percent ne-
crosis, as described below.
Treatment Received and Preop Dox DI
The number of chemotherapy cycles and the median
doses received for all 63 eligible patients are listed in
Table 3. Patients age  21 years were more likely to
receive 8 cycles of chemotherapy (23 of 29 patients;
79%) compared with patients age  21 years (18 of 34
patients; 53%).
The median preop dox DI in 56 evaluable patients
was 84% (range, 61–110%). Twenty-three of 56 evalu-
able patients (41%) received  90% of the preop dox
DI intended by the protocol. Again, preop dox DI was
related to age, with patients age  21 years receiving a
median of 90% compared with 81% in older patients
and with 54% of patients age  21 years receiving a DI
 90% compared with 29% in older patients. A higher
preop dox DI also appeared to increase the proportion
TABLE 2




0 1 2 3 4 5
Anemia 8 4 6 28 17 0
Granulocytopenia 5 0 1 8 49 0
Leukopenia 3 0 0 8 52 0
Thrombocytopenia 9 3 14 16 21 0
Cardiovascular 55 6 2 0 0 0
Flu-like symptoms 13 11 36 2 1 0
Gastrointestinal 1 13 22 22 5 0
Infection 43 0 6 12 1 1
Metabolic 57 2 2 2 0 0
Mucosal 17 12 21 9 4 0
Neuromotor 54 6 2 1 0 0
Neurosensory 36 7 15 5 0 0
Renal/bladder 43 17 1 1 1 0
822 CANCER February 15, 2004 / Volume 100 / Number 4
of good pathologic responses, as depicted in Table 4
(although the increase was not statistically signifi-
cant).
Evaluations of survival relative to patient charac-
teristics, tumor variables, and treatment delivered are
presented in Tables 5 and 6. Primary site, histology,
and preop dox DI appeared to have the most effect on
outcome, although a study of this size provides insuf-
ficient power to detect differences in survival. Patients
who were treated at institutions with more accrual (4
institutions, 35 patients) had improved survival (60%
vs. 50%) compared with centers that entered fewer
patients (20 institutions, 28 patients).
DISCUSSION
The triad that includes the patient, the malignancy,
and the therapy interacts and determines outcome in
a study. This trial showed no apparent improvement
despite alternation of a doxorubicin and ifosfamide
regimen with the standard doxorubicin and cisplatin.
Although 95% confidence intervals overlapped with
previously reported studies, including an earlier
SWOG study, recurrence free survival and overall sur-
vival rates did not approach the best prior results of a
cure rate of 70%.3–12,24
One aspect of the current study that may have
contributed to outcome is the proportion of older
patients. The median age of study participants was 22
years, and 25% of those enrolled were age  30 years,
a known adverse prognostic factor.4,25 Although the
current study did not include children age  12 years,
and the power to detect such an effect was limited by
the small sample size, the 5-year survival estimate was
higher in younger patients. Pediatric populations may
have superior outcomes, in part because of increased
tolerance of aggressive chemotherapy, as described
above. Other factors that conceivably may influence
outcomes in older patients include delay in diagnosis
and noncompliance with treatment in an adolescent
and young adult patient populations.
Adults with OS likely have a different tumor biol-
ogy with greater heterogeneity compared with chil-
TABLE 3







Doxorubicin (mg) Cisplatin (mg) Ifosfamide (g)
1 3 75 120 0
2 — — — —
3 3 200 240 8
4 6 242 240 16
5 3 295 340 16
6 3 345 360 22
7 4 405 460 22
8 41 465 480 32
TABLE 4






Fraction of patients who
achieved > 90% necrosis
% 95% CI
median: mediana 28:28 32:64 16–52:44–81
90%: 90% 33:23 36:65 20–55:43–84
Dox: doxorubicin; DI: dose intensity; 95% CI: 95% confidence interval.
a The median preoperative doxorubicin dose intensity for all 56 evaluable patients was 84%.
TABLE 5






P Value% 95% CI
Age
 22 yrs: 22 yrs 29:34 62:55 4–80:38–72 0.44
 30 yrs: 30 yrs 48:15 60:51 47–74:25–77 0.56
Gender
Male:female 44:19 58:58 44–73:36–80 0.76
Race
White:other 46:17 60:53 46–75:28–77 0.38
Tumor site
Femur:tibia:other 32:16:15 46:88:53 28–63:71–100:28–79 0.001
Histology
NOS:other 23:40 68:53 49–88:37–67 0.27
Stage (Enneking)
IIA:IIB 6:57 60:58 17–100:45–71 0.50
Symptom duration
1 mos:1–6mos:
6 mos — 86:52:64 59–100:37–67:39–89 0.39
95% CI: 95% confidence interval; NOS: not otherwise specified.
TABLE 6






P value% 95% CI
Limb salvage:amputation 44:12 61:56 47–76:26–85 0.95
% Necrosis
 90%: 90% 29:27 55:66 37–73:47–84 0.76
Preoperative Dox DI
 Median: median 28:28 49:71 30–67:55–88 0.31
95% CI: 95% confidence interval; Dox: doxorubicin; DI: dose intensity.
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dren who have this disease. Prognostic factors that
have been reported in OS include DNA ploidy; the
presence of P-glycoprotein (multidrug resistance); and
loss of heterozygosity of the RB locus and, more re-
cently, her2.26 –29 The biology of the tumors in this and
other study populations, however, is largely unknown.
Identification and recognition of the impact of these
or other variables is one strategy to evaluate results,
compare studies, and improve overall outcomes.
Response to preoperative chemotherapy has been
considered a prognostic indicator in patients with OS,
with a large majority of patients who have  90% necro-
sis at resection surviving recurrence free.8–10,13,25,30 This
parameter appears to be most predictive in programs
that have used high-dose methotrexate.10,11,31 In the cur-
rent study, nearly 50% of patients achieved a good re-
sponse, yet a correlation between necrosis and outcome
was not clear, and patients who were good responders
did not enjoy a similar reported high freedom from re-
currence. The longer duration of preoperative treatment
and the inclusion of ifosfamide in the preoperative reg-
imen may have increased the proportion of good re-
sponders and lessened the utility of scoring necrosis as a
prognostic factor, as been observed by others.12,32 In the
current multiinstitutional study, the concordance of
scoring necrosis between study and institutional pathol-
ogists was good (93%). However, processing specimens
for shipping interfered with the study pathologist receiv-
ing all specimens. Considering the good concordance
between pathologists and the lack of a clear correlation
between necrosis and outcome, it may not be necessary
to assess necrosis centrally in future multiinstitutional
studies unless postoperative therapy is dependent on
response. Instead, tissue resources and transfers may be
utilized better for confirmation of diagnosis and banking
for molecular analysis.
Based on the survival of patients without adjuvant
chemotherapy, a large majority of patients with OS
have micrometastatic disease at the time of diagnosis.
Survival is related to the burden of micrometastatic
disease, the presence of nonpulmonary metastasis,
and the chemosensitivity of disease. The numbers of
patients who progressed in the current study during
primary chemotherapy or study treatment were few,
and the fraction of good responders to primary che-
motherapy did not differ obviously from other stud-
ies.4,8,9,11,12 A long median time to recurrence and the
inability to salvage patients who developed recurrent
disease suggest a larger tumor burden, an increase in
extrapulmonary micrometastatic disease sites, and a
slower growth fraction with less inherent sensitivity to
chemotherapy.
Treatment variables include agents used as well as
dose and schedule, duration of therapy, timing and
adequacy of surgery, and DI received. Doxorubicin
and cisplatin are cornerstones of most modern OS
regimens.5,6,8,9,12,33 The protocol dose and schedule of
these agents in the current study were comparable to
those of other regimens.5,8,9,12,33 However, the dose
rate of cisplatin was lower because of the alternating
therapy. Ifosfamide has been used increasingly with
reported efficacy.32–35 High-dose methotrexate was
not included in the current study, and the impact of its
exclusion is not known. However, in randomized trials
of high-dose methotrexate, an advantage for this ap-
proach has not been established.8,15,36 –38 There was no
attempt at postoperative tailoring of chemotherapy in
this trial, although the value of that approach has not
been demonstrated clearly.9,11 The total duration of
treatment was shorter than some programs, but tox-
icity and tolerance were issues in many patients, and
completing the study treatment as outlined was diffi-
cult. Local failure was uncommon (5%); and, although
delays in surgery to 90 days may have increased the
percent of good responders to primary chemotherapy
artificially, nothing suggests that the timing of surgery
compromised overall outcomes. The DI received also
was comparable to previous reports and had no ap-
parent influence on outcome.21,39
Although combination chemotherapy clearly ap-
pears to improve outcomes for patients with OS, the
value of continuing efforts at increasing DI or adding
nonspecific cytotoxic agents seems limited. Instead,
identification and utilization of molecular markers
that are prognostic and predictive of outcome and
response to therapy are needed. Future clinical re-
search efforts should emphasize limiting exposure to
toxic and difficult therapies in patients with favorable
molecular profiles and developing targeted, specific
therapies for patients who are destined for failure with
current approaches.
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